Advertisement
"We are very excited to continue our collaboration with Aurigene. Theirbusiness model offers a one stop solution for structure guided drug design,lead optimization and preclinical work. The Debio 0617 project aims atdeveloping inhibitors targeting a key oncology pathway, which plays essentialroles in various solid tumors and haematological malignancies," saidRolland-Yves Mauvernay, President & Founder of Debiopharm Group.
Advertisement
"Partnering with Debiopharm, a highly focused and successful drugdevelopment company, is highly synergistic for Aurigene, a drug discoverybiotech. Aurigene has been collaborating with Debiopharm on two otherprograms for three years now, and the current licensing agreement withDebiopharm serves to reiterate the high quality of science and competence atAurigene. This further strengthens the relationship between the companies,"added CSN Murthy, CEO of Aurigene.
About Debiopharm Group
Debiopharm Group is a global biopharmaceutical development specialistthat in-licenses promising biologics and small molecule drug candidates. Itdevelops its products for global registration and maximum commercialpotential for out-licensing to pharmaceutical partners for sales andmarketing.
Debiopharm independently funds the worldwide development of all of itsproducts while providing expertise in pre-clinical and clinical trials,manufacturing, drug delivery and formulation, and regulatory affairs.
Founded in 1979 and headquartered in Lausanne, Switzerland, Debiopharmhas developed three products with global combined sales in excess of $2.65billion in 2007.
For more information on Debiopharm Group, please visit:http://www.debiopharm.com.
About Aurigene
Established in Bangalore, India, in 2002, Aurigene Discovery TechnologiesLtd., is a drug discovery biotech focused on small molecule and peptide drugdiscovery and development from target identification and validation topre-IND drug candidates in oncology, metabolic disorders and autoimmunediseases, with a proven track record of successful partnerships with big andmedium-sized pharma and biotech companies globally. Aurigene has 10 drugdiscovery collaborations and a pipeline of 15 discovery programs at variousstages, from Hit Generation to late-stage Pre-Clinical Optimization, and hasfiled 14 patents across 6 programs over the last 12 months.
With proprietary Structural Biology and Fragment-based Drug Designtechnology platforms, and experienced scientific leadership, Aurigene is afully integrated operation with expertise in Hit Generation to DrugDevelopment Candidates for IND nomination.Debiopharm S.A. Contacts Maurice Wagner Director Corporate Affairs & Communications Tel.: +41(0)21-321-01-11 Fax: +41(0)21-321-01-69 [email protected] Additional Media Contacts In London Maitland Brian Hudspith Tel: +44(0)20-7379-5151 [email protected] Jo-Anne Lutjens Communications Manager Tel.: +41(0)79-370-27-15 Fax: +41(0)21-321-01-69 [email protected] In New York Russo Partners, LLC Wendy Lau Tel: +1-212-845-4272 Fax: +1-212-845-4260 [email protected] Aurigene Contacts Sonita Chada Manager, Corporate Communications Tel: +91-80-2852-1314 [email protected]
SOURCE The Debiopharm Group
